RK
Raghava Kashyap
Peter MacCallum Cancer Centre, The University of Melbourne, Mahatma Gandhi Cancer Hospital
Research areas: Medicine · Radiology, Nuclear Medicine and Imaging · Medical Imaging Techniques and Applications · Radiopharmaceutical Chemistry and Applications · Neuroendocrine Tumor Research Advances
0000-0002-1007-974X
Employment
-
Peter MacCallum Cancer Centre Radionuclide Therapy Fellow2021 - Present
-
Mahatma Gandhi Cancer Hospital Chief Consultant2014 - 2021
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (90)
- Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial Save
- Prognostic Value of Restaging [18F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Therapy Save
- Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis Save
- Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial Save
- First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study Save
- Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials Save
- Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours – a single centre experience Save
- First-in-human results of terbium-161[ 161 Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase I/II study. Save
- Role of neoadjuvant peptide receptor radionuclide therapy in unresectable and metastatic gastro‐entero‐pancreatic neuroendocrine neoplasms: A scoping review Save
- Deep Learning for Automated Measures of SUV and Molecular Tumor Volume in [68Ga]PSMA-11 or [18F]DCFPyL, [18F]FDG, and [177Lu]Lu-PSMA-617 Imaging with Global Threshold Regional Consensus Network Save
- Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study Save
- Single Time Point Whole-Body Tumour Dosimetry as an Independent Prognostic Biomarker for Treatment Outcome in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Lutetium-177 [177Lu]Lu-PSMA-617 Save
- Therapy-related Myeloid Neoplasms Following Lutetium-177 [177Lu]Lu-PSMA Therapy in patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series Save
- Discontinuing [177Lu]Lu-PSMA-617 radioligand therapy solely on PSA response after first cycle is not advisable: insights from a prospective registry Save
- Radiation absorbed dose in patients with metastatic castration-resistant prostate cancer treated with [161Tb]Tb-PSMA-I&T Save
- ‘Case of the Month’ from Peter MacCallum Cancer Centre, Melbourne, Australia: insidious presentation of iatrogenic renal pelvis injury following ureteric cannulation with 5-F catheter diagnosed on unconventional mercaptoacetyltriglycine and single-photon… Save
- Clinical Positron Emission Tomography/Computed Tomography: Quarter-Century Transformation of Prostate Cancer Molecular Imaging Save
- Correlation of current myocardial perfusion imaging and previous coronary angiography to avert the need for repeat intervention – A case report Save
- Automated AI Tumor Burden Analysis on Lu-177 PSMA Quantitative SPECT with Global Threshold Regional Consensus Network (GTRC-Net) Save
- Could FAP-Targeted Molecular Imaging Replace18F-FDG for Standard-of-Care Oncologic PET? Save